Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral nutrition (HPN). Denosumab represent a new drug, which helped to prevent osteoclast. The aim of the study was to assess its value in chronic intestinal failure patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanley Dudrick's Memorial Hospital
• Treatments: Denosumab

Criteria

Inclusion Criteria:

• intestinal failure requiring home parental nutrition

• bone disease measurement

Exclusion Criteria:

• intestinal failure not requiring HPN

• diagnostic modalities impossible